Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Biotech
Hepatitis B drug developers chart slow progress, just like hep C
Even as other liver diseases have gained investor interest, hepatitis B drug developers are bullish about finding a functional cure.
Max Bayer
Nov 14, 2023 9:05am
Inventiva stock climbs on delayed data from liver disease trial
Jun 14, 2023 6:00am
Organoids offer NAFLD insights and potential drug target
Feb 28, 2023 12:27pm
J&J strikes down Arrowhead NASH pact; fate of hep B deal unknown
Feb 15, 2023 9:22am
Madrigal's stock enters orbit after 2nd phase 3 NASH success
Dec 19, 2022 10:05am
Nicotine-nomming gut bacteria could protect against NASH
Oct 21, 2022 1:05pm
